‘Is this the next Theranos?’ How Elizabeth Holmes changed health-tech investing

Photo: Blood test samples in test tubes. Photo credit: National Cancer Institute on Unsplash. Article by Ruth Reader. Fast Company – September 8, 2021.

Investors continue to pour billions into health-technology companies, but have become more skeptical, some VCs say.

Theranos founder Elizabeth Holmes is on trial today for defrauding both customers and investors, reigniting conversation about the company and the impact it’s had on investment in the health-technology space.

Holmes’s company developed a machine called Edison, which she claimed could run a myriad of diagnostic tests using a mere pinprick’s worth of blood or a much smaller volume than is typical. However, a 2015 report from The Wall Street Journal found that the company was only using its own technology for a fraction of the tests it offered and […]

Click here to view original web page at www.fastcompany.com